Prospective, controlled, multi-centre study on feasibility and effectiveness of pharmaceutical care for tumor patients including therapeutic drug monitoring of selected anticancer drugs

Not Applicable

• Conditions: C50; C56; Malignant neoplasm of breast; Malignant neoplasm of ovary

• Registration Number: DRKS00000765
• Lead Sponsor: Pharmazeutisches Institut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2005-11-30
• Study Start: 2011-03-29
• Results First Posted: 2012-02-02
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

Diagnosis of breast or ovarian cancer, first treatment with chemotherapy, written informed consent, ability to speak, read and write German

Exclusion Criteria

Diseases which impeded that the patient completely understood the provided information on the study or if the patient had an impaired capability of reading and completing questionnaires self-administered (e.g. Alzheimer)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete antiemetic response, defined as no emetic episode on five days following chemotherapy, documented in a standardized patient diary

Secondary Outcome Measures

Name	Time	Method
Frequency of emetic episodes and severity of nausea, documented in a standardized patient diary; quality of life, measured using the EORTC QLQ-C30 questionnaire 3 and 6 months after start of chemotherapy; patient satisfaction with information, measured using the PS-CaTE questionnaire 6 months after start of chemotherapy